Recent advances in the treatment of colonic diverticular disease and prevention of acute diverticulitis

Annals of Gastroenterology

Volumn 29, Issue 1, 2016, Pages 24-32

  Elisei, Walter ^a   Tursi, Antonio ^b  

^a ASL Roma H   (Italy)

^b ASL BAT   (Italy)

Author keywords

5 aminosalicylic acid; Acute diverticulitis; Diverticular disease; High fiber diet; Nonabsorbable antibiotics; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; BALSALAZIDE; MANNAN; MESALAZINE; METHYLCELLULOSE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; SPASMOLYTIC AGENT;

ABDOMINAL PAIN; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COLON DIVERTICULOSIS; DIET SUPPLEMENTATION; DIETARY FIBER; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HUMAN; LACTOBACILLUS CASEI; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; VEGETARIAN DIET;

EID: 84953897233     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Tursi A, Papagrigoriadis S. Review article: the current and evolving treatment of colonic diverticular disease. Aliment Pharmacol Ther 2009;30:532-546.
2. Weizman AV, Nguyen GC. Diverticular disease: epidemiology and management. Can J Gastroenterol 2011;25:385-389.
3. Strate LL, Modi R, Cohen E, Spiegel BM. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. Am J Gastroenterol 2012;107:1486-1493.
4. Tursi A. New physiopathological and therapeutic approaches to diverticular disease: an update. Expert Opin Pharmacother 2014;15:1005-1017.
5. Kohler L, Sauerland S, Neugebauer E. Diagnosis and treatment of diverticular disease: result of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery. Surg Endosc 1999;13:430-436.
6. Yamada E, Inamori M, Uchida E, et al. Association between the location of diverticular disease and the irritable bowel syndrome: a multicenter study in Japan. Am J Gastroenterol 2014;109:1900-1905.
7. Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Trichopoulos DV, Willett WC. Prospective study of diet and the risk of symptomatic diverticular disease in men. Am J Clin Nutr 1994;60:757-764.
8. Costedio MM, Coates MD, Danielson AB, et al. Serotonin signaling in diverticular disease. J Gastrointest Surg 2008;12:1439-1445.
9. Tursi A, Elisei W, Giorgetti GM, et al. Detection of endoscopic and histological inflammation after an attack of colonic diverticulitis is associated with higher diverticulitis recurrence. J Gastrointestin Liver Dis 2013;22:3-9.
10. Cuomo R, Barbara G, Andreozzi P, et al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest 2013;43:1147-1155.
11. Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Faecal calprotectin in colonic diverticular disease: a casecontrol study. Int J Colorectal Dis 2009;24:49-55.
12. Tursi A. Diverticular disease and irritable bowel syndrome: it’s time to diff erentiate. Am J Gastroenterol 2015;110:774-775.
13. Humes D, Simpson J, Spiller RC. Colonic diverticular disease. BMJ Clin Evid 2007;pii:0405.
14. Simpson J, Scholefield JH, Spiller RC. Origin of symptoms in diverticular disease. Br J Surg 2003;90:899-908.
15. von Rahden BA, Germer CT. Pathogenesis of colonic diverticular disease. Langenbecks Arch Surg 2012;397:1025-1033.
16. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive disease in the United States. Gastroenterology 2002;122:1500-1511.
17. Lahat A, Avidan B, Sakhnini E, Katz L, Fidder HH, Meir SB. Acute diverticulitis: a decade of prospective follow-up. J Clin Gastroenterol 2013;47:415-419.
18. Stollman N, Raskin JB. Diagnosis and management of diverticular disease of the colon in adults: Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999;94:3110-3121.
19. Chautems R, Ambrosetti P, Ludwig A, Mermillod B, Morel P, Soravia C. Long term follow-up after first acute episode of sigmoid diverticulitis: is surgery mandatory? A prospective study of 118 patients. Dis Colon Rectum 2002;45:962-966.
20. Chapman J, Dozois EJ, Wolff BG, Gullerud RE, Larson DR. Diverticulitis: a progressive disease? Do multiple recurrences predict less favourable outcomes ? Ann Surg 2006;243:876-880.
21. Hart AR, Kennedy HJ, Stebbings WS, Day NE. How frequently do large bowel diverticula perforate? An incidence and cross-sectional study. Eur J Gastroenterol Hepatol 2000;12:661-665.
22. Richards R, Hammitt JK. Timing of prophylactic surgery in prevention of diverticulitis recurrence: a cost-effectiveness analysis. Dig Dis Sci 2002;47:1903-1908.
23. Salem L, Veenstra DL, Sullivan SD, Flum DR. The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg 2004;199:904-902.
24. Rafferty J, Shellito P, Hyman NH, Buie WD; Standards Committee of American Society of Colon and Rectal Surgeons. Practice parameters for sigmoid diverticulitis. Dis Colon Rectum 2006;49:939-944.
25. World Gastroenterology Organisation (WGO) Practice Guidelines. Diverticular disease, 2007. http://www.worldgastroenterology.org/assets/downloads/en/pdf/guidelines/07_diverticular_disease pdf 2007.
26. Ünlü C, Daniels L, Vrouenraets BC, Boermeester MA. A systematic review of high-fiber dietary therapy in diverticular disease. Int J Colorectal Dis 2012;27:419-427.
27. Brodribb AJ. Treatment of symptomatic diverticular disease with a high fiber diet. Lancet 1977;1:664-666.
28. Hodgson WJ. The placebo effect. Is it important in diverticular disease? Am J Gastroenterol 1977;67:157-162.
29. Peery AF, Barrett PR, Park D, et al. A high-fiber diet does not protect against asymptomatic diverticulosis. Gastroenterology 2012;142:266-267.
30. Lamanna A, Orsi A. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia 1984;3:365-367.
31. Bianchi M, Festa V, Moretti A, et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther 2011;33:902-910.
32. MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol 2000;95:3343-3345.
33. Trespi E, Colla C, Panizza P, et al. Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results. Minerva Gastroenterol Dietol 1999;45:245-252. (Article in Italian)
34. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepatogastroenterology 2008;55:916-920.
35. Kruis W, Meier E, Schumacher M, Mickisch O, Greinwald R, Mueller R; German SAG-20 Study Group. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo-controlled study. Aliment Pharmacol Ther 2013;37:680-690.
36. Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 2013;38:741-751.
37. Smith J, Humes D, Garsed K, et al. Mechanistic randomised control trial of mesalazine in symptomatic diverticular disease. Gut 2012;61:A51-A52.
38. Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez- Llorente C, Gil A. Probiotic mechanism of action. Ann Nutr Metab 2012;61:160-174.
39. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006;40:312-316.
40. Annibale B, Maconi G, Lahner E, De Giorgi F, Cuomo R. Efficacy of Lactobacillus paracasei sub. paracasei F19 on abdominal symptoms in patients with symptomatic uncomplicated diverticular disease: a pilot study. Minerva Gastroenterol Dietol 2011;57:13-22.
41. Lahner E, Esposito G, Zullo A, et al. High-fiber diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World J Gastroenterol 2012;18:5918-5924.
42. Feingold D, Steele SR, Lee S, et al. Practice parameters for the treatment of sigmoid diverticulitis. Dis Colon Rectum 2014;57:284-294.
43. Leahy AL Ellis RM, Quill DS, Peel AL. High fiber diet in symptomatic diverticular disease of the colon. Ann R Coll Surg Engl 1985;67:173-174.
44. Crowe FL, Appleby PN, Allen NE, Key TJ. Diet and risk of diverticular disease in Oxford cohort of European Prospective Investigation into Cancer and Nutrition (EPIC): prospective study of British vegetarians and non-vegetarians. BMJ 2011;343:d4131.
45. Ornstein MH, Littlewood ER, Baird IM, Fowler J, North WR, Cox AG. Are fiber supplements really necessary in diverticular disease of the colon? A controlled clinical trial BMJ 1981;282:1353-1356.
46. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995;9:33-39.
47. Latella G, Pimpo MT, Sottili S, et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003;18:55-62.
48. Papi C Ciaco A, Koch M, Capurso L. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon: a pilot multicentre open trial. Diverticular Disease Study Group. Ital J Gastroenterol 1992;24:452-456.
49. Colecchia A, Vestito A, Pasqui F, et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 2007;13:264-269.
50. Cohen E, Fuller G, Bolus R, et al. Increased risk for irritable bowel syndrome aft er acute diverticulitis. Clin Gastroenterol Hepatol 2013;11:1614-1649.
51. Di Mario F, Aragona G, Leandro G, et al. Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci 2005;50:581-586.
52. Comparato G, Fanigliulo L, Cavallaro LG. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 2007;52:2934-2941.
53. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci 2007;52:671-674.
54. Ghorai S, Ulbright TM, Rex DK. Endoscopic fi ndings of diverticular inflammation in colonoscopy patients without clinical acute diverticulitis: prevalence and endoscopic spectrum. Am J Gastroenterol 2003;98:802-806.
55. Tursi A, Elisei W, Giorgetti GM, Aiello F, Brandimarte G. Inflammatory manifestations at colonoscopy in patients with colonic diverticular disease. Aliment Pharmacol Ther 2011;33:358-365.
56. Tursi A, Brandimarte G, Di Mario F, et al. Development and validation of an endoscopic classifi cation of diverticular disease of the colon: The DICA classification. Dig Dis 2015;33:68-76.